Rationale-based design of a targeted therapy for cancer
US10449202B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 18, 2017 |
| Grant date | Oct 22, 2019 |
| Priority date | — |
| Expiry date | Jul 18, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/5011
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.